CY1121166T1 - Ενωσεις για τη θεραπεια παχυσαρκιας και μεθοδοι χρησης αυτων - Google Patents

Ενωσεις για τη θεραπεια παχυσαρκιας και μεθοδοι χρησης αυτων

Info

Publication number
CY1121166T1
CY1121166T1 CY20181101181T CY181101181T CY1121166T1 CY 1121166 T1 CY1121166 T1 CY 1121166T1 CY 20181101181 T CY20181101181 T CY 20181101181T CY 181101181 T CY181101181 T CY 181101181T CY 1121166 T1 CY1121166 T1 CY 1121166T1
Authority
CY
Cyprus
Prior art keywords
weight loss
obese
administered
loss agents
obesity
Prior art date
Application number
CY20181101181T
Other languages
Greek (el)
English (en)
Inventor
Umut Ozcan
Joseph MAJZOUB
Ralph Mazitschek
Isin CAKIR
Serkan CABI
Original Assignee
The Children's Medical Center Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304418&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1121166(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The Children's Medical Center Corporation filed Critical The Children's Medical Center Corporation
Publication of CY1121166T1 publication Critical patent/CY1121166T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CY20181101181T 2012-09-27 2018-11-08 Ενωσεις για τη θεραπεια παχυσαρκιας και μεθοδοι χρησης αυτων CY1121166T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261706153P 2012-09-27 2012-09-27
PCT/US2013/061911 WO2014052583A1 (en) 2012-09-27 2013-09-26 Compounds for the treatment of obesity and methods of use thereof

Publications (1)

Publication Number Publication Date
CY1121166T1 true CY1121166T1 (el) 2020-05-29

Family

ID=49304418

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181101181T CY1121166T1 (el) 2012-09-27 2018-11-08 Ενωσεις για τη θεραπεια παχυσαρκιας και μεθοδοι χρησης αυτων

Country Status (21)

Country Link
US (6) US9968575B2 (enExample)
EP (3) EP3434268B1 (enExample)
JP (2) JP6480864B2 (enExample)
CN (3) CN111529535A (enExample)
AU (3) AU2013323528B2 (enExample)
BR (1) BR112015006848A2 (enExample)
CA (2) CA3030272C (enExample)
CY (1) CY1121166T1 (enExample)
DK (1) DK2900230T3 (enExample)
ES (1) ES2696626T3 (enExample)
HR (1) HRP20181879T1 (enExample)
HU (1) HUE040496T2 (enExample)
LT (1) LT2900230T (enExample)
PL (1) PL2900230T3 (enExample)
PT (1) PT2900230T (enExample)
RS (1) RS58010B1 (enExample)
RU (2) RU2768868C2 (enExample)
SI (1) SI2900230T1 (enExample)
SM (1) SMT201800604T1 (enExample)
TR (1) TR201815668T4 (enExample)
WO (1) WO2014052583A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3434268B1 (en) * 2012-09-27 2022-04-20 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
CN117357538A (zh) * 2014-03-26 2024-01-09 儿童医学中心公司 用于治疗肥胖症的雷公藤红素和衍生物
WO2015153933A1 (en) * 2014-04-03 2015-10-08 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
CN105985401B (zh) * 2015-02-16 2020-10-09 上海华拓医药科技发展有限公司 一种雷公藤红素衍生物、其制备方法及用途
US10662218B2 (en) * 2015-10-23 2020-05-26 Erx Pharmaceuticals, Inc. Analogs of celastrol
CN106905404B (zh) * 2017-01-13 2019-08-27 广东工业大学 熊果酸衍生物及其制备方法和应用
CN116509842B (zh) * 2021-09-09 2024-09-20 厦门君德医药科技有限公司 药物组合物及其制备方法和应用
KR102470686B1 (ko) * 2022-06-07 2022-11-23 서울대학교산학협력단 디메틸제일아스테럴을 포함하는 대사성 질환 예방 또는 치료용 약학 조성물
CN119431489A (zh) * 2024-11-13 2025-02-14 肇源县总医院 一种雷公藤红素衍生物及其制备方法

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
MY107937A (en) 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US5827734A (en) 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
US5552523A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5532336A (en) 1995-01-31 1996-07-02 Eli Lilly And Company Anti-obesity proteins
US5552524A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5552522A (en) 1995-01-31 1996-09-03 Eli Lilly And Company Anti-obesity proteins
US5521283A (en) 1995-01-31 1996-05-28 Eli Lilly And Company Anti-obesity proteins
WO1996040912A1 (en) 1995-06-07 1996-12-19 Amgen Inc. Ob protein compositions and method
IL122718A0 (en) 1995-06-30 1998-08-16 Lilly Co Eli Methods for treating diabetes
EP0865294B1 (en) 1995-08-17 2004-02-18 Amgen Inc. Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions
US5650167A (en) * 1995-11-16 1997-07-22 Dawa Incorporated Method and composition for treating hepatitis B
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
ES2217327T3 (es) 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
WO1997038014A1 (en) 1996-04-04 1997-10-16 Amgen Inc. Fibulin pharmaceutical compositions and related methods
JP2001501177A (ja) 1996-08-30 2001-01-30 アムジエン・インコーポレーテツド Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法
BR9711513A (pt) 1996-09-20 1999-08-24 Hoechst Ag Uso de antagonistas de leptina para o tratamento de resistencia a insulina em diabete do tipo ii
EP0839525B1 (en) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5880116A (en) * 1996-12-13 1999-03-09 Neurocal International Use of celastrol to treat alzheimer's disease
EA004790B1 (ru) 1996-12-20 2004-08-26 Амген Инк. Композиции на основе слитого белка ов и способы их применения
ATE223229T1 (de) 1997-04-17 2002-09-15 Amgen Inc Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
TR199902980T2 (xx) 1997-06-06 2000-05-22 Smithkline Beecham P.L.C. Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�.
US7052678B2 (en) 1997-09-15 2006-05-30 Massachusetts Institute Of Technology Particles for inhalation having sustained release properties
US6541033B1 (en) 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
PT1107793E (pt) 1998-08-10 2005-02-28 Amgen Inc Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
AU6396999A (en) 1998-10-02 2000-04-26 Amgen, Inc. Method to determine a predisposition to leptin treatment
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CA2359840C (en) 1999-02-12 2012-10-23 Amgen Inc. Glycosylated leptin compositions and related methods
PL214862B1 (pl) 2001-10-22 2013-09-30 Amgen Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny
NZ539642A (en) * 2002-10-21 2007-01-26 Metaproteomics Llc Compositions containing extracts from hops in combination with a second component for treating inflammatory response
WO2004039832A2 (en) 2002-10-31 2004-05-13 Albany Medical College Leptin-related peptides
RU2346688C2 (ru) * 2002-12-06 2009-02-20 Фиброген, Инк. Регулирование содержания жира
EP1715539B1 (en) 2004-01-16 2012-11-07 Mitsubishi Materials Corporation Separator for fuel cell, method of producing separator, and solid oxide fuel cell
US20060253100A1 (en) * 2004-10-22 2006-11-09 Medtronic, Inc. Systems and Methods to Treat Pain Locally
JP4169777B2 (ja) 2005-09-30 2008-10-22 森永乳業株式会社 インスリン抵抗性改善剤
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
AU2007230991A1 (en) 2006-03-22 2007-10-04 Syndexa Pharmaceuticals Corporation Compounds and methods for treatment of disorders associated with ER stress
WO2007117466A2 (en) * 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
WO2008021210A2 (en) 2006-08-11 2008-02-21 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
JPWO2008020622A1 (ja) * 2006-08-17 2010-01-07 杏林製薬株式会社 新規なチエノ［２，３−ｄ］ピリミジン化合物
WO2008063513A2 (en) 2006-11-13 2008-05-29 Trustees Of Columbia University In The City Of New York Selective proteasome inhibitors for treating diabetes
CN101279995A (zh) * 2007-04-03 2008-10-08 烟台靶点药物研究有限公司 一种雷公藤红素盐及其制备方法与用途
WO2009026163A1 (en) 2007-08-17 2009-02-26 Burnham Institute For Medical Research Compositions and methods for inhibiting growth and metastasis of melanoma
BRPI0722276A2 (pt) * 2007-11-14 2014-04-22 Amylin Pharmaceuticals Inc Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
CN101434635B (zh) 2007-11-16 2012-05-16 上海华拓医药科技发展股份有限公司 一类具抗肿瘤活性的水溶性酚性三萜化合物及其制备方法
WO2009067245A2 (en) * 2007-11-20 2009-05-28 University Of Florida Research Foundation, Inc. Compositions and methods for tissue repair
AU2009332930A1 (en) * 2008-02-01 2009-08-13 The Scripps Research Institute Methods for treating a condition characterized by dysfunction in protein homeostasis
CN101352444A (zh) * 2008-09-11 2009-01-28 中国科学院广州生物医药与健康研究院 雷公藤红素在制药中的新应用
WO2010119674A1 (ja) * 2009-04-17 2010-10-21 国立大学法人広島大学 レプチン抵抗性を改善および／または予防するための薬学的組成物、並びにその使用
CN101704874A (zh) * 2009-11-26 2010-05-12 中国药科大学 五环三萜及其衍生物的二甲双胍盐、其制备方法及医药用途
MY163031A (en) 2010-04-12 2017-07-31 Reata Pharmaceuticals Inc Method of treating obesity using antioxidant inflammation modulators
CN101805390B (zh) 2010-04-13 2012-07-18 暨南大学 一种雷公藤红素衍生物及其用途
CN102309494A (zh) * 2010-07-01 2012-01-11 嘉兴学院 扁蒴藤素作为炎性细胞因子抑制剂的医药用途
US8691977B2 (en) 2010-08-23 2014-04-08 Neupharma, Inc. Certain chemical entities, compositions, and methods
JP5816626B2 (ja) * 2010-09-17 2015-11-18 武田薬品工業株式会社 糖尿病治療剤
KR101180387B1 (ko) 2011-11-21 2012-09-10 동국대학교 산학협력단 엣지 추출을 위한 이미지 센서 및 이를 이용한 엣지 이미지 생성 방법.
KR20150010793A (ko) 2012-05-25 2015-01-28 버그 엘엘씨 열 충격 단백질 (hsp) 90-베타의 조절에 의한 대사 증후군의 치료 방법들
EP3434268B1 (en) * 2012-09-27 2022-04-20 The Children's Medical Center Corporation Compounds for the treatment of obesity and methods of use thereof
CN103524592B (zh) 2013-09-27 2015-08-05 安徽医科大学 一种雷公藤红素衍生物、该衍生物的生物盐及其制备方法与用途
US9601471B2 (en) 2015-04-23 2017-03-21 Apple Inc. Three layer stack structure

Also Published As

Publication number Publication date
US20210275482A1 (en) 2021-09-09
BR112015006848A2 (pt) 2018-05-22
EP2900230B1 (en) 2018-08-15
RU2650646C2 (ru) 2018-04-16
US20180185314A1 (en) 2018-07-05
CA2886393A1 (en) 2014-04-03
CN111529534A (zh) 2020-08-14
HK1213190A1 (en) 2016-06-30
RU2018112067A3 (enExample) 2021-06-24
AU2018256619A1 (en) 2018-11-22
TR201815668T4 (tr) 2018-11-21
AU2016247206A1 (en) 2016-11-10
SI2900230T1 (sl) 2019-01-31
RU2768868C2 (ru) 2022-03-25
WO2014052583A1 (en) 2014-04-03
EP2900230A1 (en) 2015-08-05
AU2013323528A1 (en) 2015-04-09
JP2015531376A (ja) 2015-11-02
CA3030272C (en) 2021-09-28
US12064408B2 (en) 2024-08-20
ES2696626T3 (es) 2019-01-17
US20250161252A1 (en) 2025-05-22
CN111529535A (zh) 2020-08-14
PL2900230T3 (pl) 2019-02-28
US20210008019A1 (en) 2021-01-14
US11045439B2 (en) 2021-06-29
EP3434268B1 (en) 2022-04-20
SMT201800604T1 (it) 2019-01-11
CA2886393C (en) 2019-02-26
HRP20181879T1 (hr) 2019-02-08
PT2900230T (pt) 2018-11-26
EP3434268A1 (en) 2019-01-30
JP2019070052A (ja) 2019-05-09
JP6743211B2 (ja) 2020-08-19
AU2018256619B2 (en) 2020-07-23
US9968575B2 (en) 2018-05-15
CA3030272A1 (en) 2014-04-03
AU2013323528B2 (en) 2016-11-10
RU2015115696A (ru) 2016-11-20
RS58010B1 (sr) 2019-02-28
US9925161B2 (en) 2018-03-27
US20150250753A1 (en) 2015-09-10
CN104822374A (zh) 2015-08-05
LT2900230T (lt) 2019-01-10
AU2016247206B2 (en) 2018-08-02
EP4082541A1 (en) 2022-11-02
DK2900230T3 (en) 2018-11-12
HUE040496T2 (hu) 2019-03-28
JP6480864B2 (ja) 2019-03-13
RU2018112067A (ru) 2019-03-07
US20170304245A1 (en) 2017-10-26
US10653654B2 (en) 2020-05-19

Similar Documents

Publication Publication Date Title
CY1121166T1 (el) Ενωσεις για τη θεραπεια παχυσαρκιας και μεθοδοι χρησης αυτων
CY1123388T1 (el) Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας
JOP20200222A1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
CY1122624T1 (el) Θεραπεια συνδυασμου του καρκινου
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1124078T1 (el) Συνθεσεις που περιλαμβανουν αναστολεα λυσινης ειδικης απομεθυλασης-1 που εχει δακτυλιο πυριμιδινης και χρηση αυτων στη θεραπεια καρκινου
PH12014500386A1 (en) Combination treatment for hepatitis c
MA34019B1 (fr) Aryltriazolone liée à un bis-aryle et son utilisation
BR112015020453A8 (pt) "formas de dosagem de liberação prolongada orais de tofacitinibe e uso de tofacitinibe
MX2017015226A (es) Compuestos alqueno tetrasustituidos y su uso.
MX2018001723A (es) Conjugados farmaco-multiligando y usos de los mismos.
AR092177A1 (es) Metodos para tratar o prevenir asma administrando un antagonista de il-4r
MX384234B (es) Uso de pridopidina para el tratamiento de enfermedad de huntington.
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
AR091876A1 (es) Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
MX2013007189A (es) Metodos y composiciones adecuados para manejar glucosa en sangre en animales.
MX382516B (es) Composiciones y metodos para absorcion transmucosa.
MX379043B (es) Uso de sobetirome en el tratamiento de enfermedades de mielinización.
BR112014018953A8 (pt) Derivados de lupano triterpenoide e uso farmacêutico dos mesmos
BR112016021985A8 (pt) formulação farmacêutica e composto
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
CY1122551T1 (el) Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων
PE20181332A1 (es) Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos